Abbott Laboratories (NY: ABT )
122.21 USD +2.43 (+2.03%) Official Closing Price Updated: 5:40 PM EST, Mar 1, 2021 Add to My Watchlist
Press releases about Abbott Laboratories
He's Back and He's Hydrated: Abbott and NFL Star Odell Beckham Jr. Partner for Pedialyte®
September 06, 2019
Abbott Launches World's First Pivotal Trial to Test New Approach for Repairing Leaky Tricuspid Heart Valves
September 05, 2019
- TRILUMINATE Pivotal trial is the world's first randomized clinical trial to evaluate transcatheter tricuspid valve repair in patients with severe tricuspid regurgitation
Surmodics has completed enrollment in TRANSCEND, its pivotal clinical trial for the SurVeil™ drug-coated balloon.
New Study Finds Abbott's Blood Test Technology Could Help Detect Brain Injury Quickly, Even if CT Scan is Normal
August 26, 2019
- The TRACK-TBI study found that 64% of people with the highest levels of a protein in the blood were confirmed to have brain injury through an MRI scan, even when a CT scan did not detect it
Together, We Can Increase the Number of Women in STEM: Here is a Tool to Help Companies Get Started
August 26, 2019
- On Women's Equality Day, Abbott is publishing a blueprint for creating a high school STEM internship aimed at exposing young people, particularly girls, to STEM early and empowering other companies...
Abbott and Intoximeters Partner to Keep Roads Safer by Bringing Together Industry-leading Technology for Drug and Alcohol Testing
August 14, 2019
- Agreement gives law enforcement access to the most advanced handheld tools to help detect drug and alcohol-impaired drivers
Absolute (TSX: ABT) (“Absolute” or the “Company”), the leader in endpoint resilience, today announced its financial results for the three months and year ended June 30, 2019. All dollar figures are...
Absolute Names Lynn Atchison to Board of Directors
August 08, 2019
Absolute (TSX: ABT), the leader in endpoint resilience, today announced Lynn Atchison has joined Absolute's Board of Directors effective as of August 7, 2019. Ms. Atchison will also serve on the Audit...
Absolute to Host Conference Call for Fiscal 2019 Fourth Quarter and Annual Financial Results
July 30, 2019
Absolute (TSX: ABT), the leader in endpoint resilience, today announced it will host a conference call on Tuesday, August 13, 2019 at 5:00 ET (2:00 p.m. PT) to discuss its fiscal 2019 fourth quarter...
Absolute Announces Significant Updates to its Enterprise Resilience Edition, Simplifying Security Policy Deployments and Remote Management of Device Fleets
July 24, 2019
Absolute (TSX: ABT), the leader in endpoint resilience, today announced the latest update to its Enterprise Resilience Edition. The new release provides customers with increased operational efficiency,...
Absolute Declares Quarterly Dividend
July 19, 2019
Absolute (TSX: ABT), the leader in endpoint resilience, today announced that its Board of Directors has declared a quarterly dividend of CAD$0.08 per share on its common shares, payable in cash on...
Tags Featured News
Abbott Reports Second-Quarter 2019 Results
July 17, 2019
Abbott Receives U.S. Approval of Next-Generation MitraClip®, Bringing New Enhancements to Abbott's Leading MitraClip Platform
July 15, 2019
Abbott Announces FDA Approval of the Alinity™ s System, the Latest Technology for Screening and Protecting the U.S. Blood and Plasma Supply
July 11, 2019
- Alinity™ s System will screen the U.S. blood and plasma supply faster and more efficiently while maintaining highest levels of accuracy
- Real-world data from Advocate Health Care and Abbott shows prioritizing nutrition care for home health patients helped keep them out of the hospital
Abbott Hosts Conference Call for Second-Quarter Earnings
June 19, 2019
Abbott (NYSE: ABT) will announce its second-quarter 2019 financial results on Wednesday, July 17, 2019, before the market opens.
CARE, Abbott and the Abbott Fund Launch Partnership to Address Noncommunicable Diseases (NCDs) in Humanitarian Settings
June 17, 2019
Abbott Launches First-ever Rapid Point-of-Care HbA1c Test to Aid in the Diagnosis of Diabetes
June 17, 2019
- Afinion™ HbA1c Dx test provides results in three minutes, enabling clinicians to develop informed, individualized care plans during patient consultation
Abbott Declares 382ⁿᵈ Consecutive Quarterly Dividend
June 14, 2019
The board of directors of Abbott (NYSE: ABT) today declared a quarterly common dividend of 32 cents per share.
- 45% of blood donations have historically come from people over 50 years old, but that number is declining 1
New Data Show Use of Abbott's FreeStyle® Libre System Significantly Reduces HbA1c Levels in People Living with Type 2 Diabetes
June 08, 2019
- Presented as a late-breaker at the American Diabetes Association (ADA) 79 th Scientific Sessions, new real-world data demonstrate that monitoring glucose with FreeStyle Libre System has a positive...
Absolute (TSX: ABT), the leader in endpoint resilience, today announced the appointment of three key executives to its leadership team. Sandra Toms joins the team as Chief Marketing Officer (CMO),...
TRILUMINATE Study Shows Treatment with Abbott's First-of-its-Kind Minimally Invasive Device Reduces Tricuspid Heart Valve Leaks
May 21, 2019
- Late-breaking data for Abbott's investigational clip-based tricuspid heart valve repair system presented at EuroPCR
New ZonePerfect® Keto is 100% #TrueKeto with the Proven Blend of Macros for Effective Results
May 16, 2019
- Abbott's ZonePerfect Keto shakes and powders are formulated with a science-based macronutrient ("macros") ratio of 75% fat, 20% protein and 5% carbohydrates to support ketosis and burn body fat
Nearly 9 out of 10 College Students with Student Debt Say It's Important to Find a Company That Offers Loan Relief
May 15, 2019
- The YouGov-Abbott Student Loan Impact Survey shows 87% of those in college or graduating this year with student debt say finding a company with a student loan benefit is important to them
Abbott Partners With NIH On BRAIN Initiative to Advance Research for Neurological Disorders
May 14, 2019
- Partnership with NIH aims to increase understanding and accelerate the application of neurostimulation therapies